Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis

被引：24

作者：

Lingscheid, Tilman ^{[1
,2
,3
]}

Kinzig, Martina ^{[4
]}

Krueger, Anne ^{[2
,3
,5
]}

Mueller, Nils ^{[2
,3
,5
]}

Boelke, Georg ^{[2
,3
,5
]}

Tober-Lau, Pinkus ^{[1
,2
,3
]}

Muenn, Friederike ^{[1
,2
,3
]}

Kriedemann, Helene ^{[1
,2
,3
]}

Witzenrath, Martin ^{[1
,2
,3
,6
]}

Sander, Leif E. ^{[1
,2
,3
,6
,7
]}

Soergel, Fritz ^{[4
,8
]}

Kurth, Florian ^{[1
,2
,3
,9
]}

机构：

[1] Charite Univ Med Berlin, Dept Infect Dis & Resp Med, Berlin, Germany

[2] Free Univ Berlin, Berlin, Germany

[3] Humboldt Univ, Berlin, Germany

[4] IBMP Inst Biomed & Pharmaceut Res, Nurnberg, Germany

[5] Charite Univ Med Berlin, Dept Nephrol & Intens Care, Berlin, Germany

[6] DZL, German Ctr Lung Res, Berlin, Germany

[7] Berlin Inst Hlth, Berlin, Germany

[8] Univ Duisburg Essen, West German Heart & Vasc Ctr, Inst Pharmacol, Essen, Germany

[9] Bernhard Nocht Inst Trop Med, Dept Trop Med, Hamburg, Germany

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2022年 / 66卷 / 11期

关键词：

COVID-19; end-stage renal disease; hemodialysis; nirmatrelvir/ritonavir; Paxlovid; PLASMA;

D O I：

10.1128/aac.01229-22

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Nirmatrelvir/ritonavir is an effective antiviral therapy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Use is not recommended in patients with end-stage renal disease (ESDR) due to a lack of data. We investigated the pharmacokinetics of nirmatrelvir/ritonavir (150 mg/100 mg twice a day) in four patients with ESRD undergoing hemodialysis. Nirmatrelvir peak concentrations ranged from 4,563 to 7,898 ng/ mL and declined after hemodialysis. Concentrations were up to 4-fold higher but still within the range known from patients without ESRD, without accumulation of nirmatrelvir after the end of treatment.

引用

页数：4

共 50 条

[1] Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
Lu, Jiayue
Cai, Hong
Hao, Yujun
Lin, Zhang
Liu, Shang
Zhan, Yaping
Ding, Li
Huang, Meilan
Li, Zhenyuan
Xu, Lan
Yan, Xiujuan
Yang, Li
Zhang, He
Zhang, Wei
Zhao, Li
Zhao, Junli
Wang, Ting
Gu, Leyi
FRONTIERS IN PHARMACOLOGY, 2023, 14
[2] Impact of the COVID-19 pandemic on the management of patients with end-stage renal disease
Li, Szu-Yuan
Tang, Yu-Shuo
Chan, Yu-Jiun
Tarng, Der-Cherng
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (07) : 628 - 633
[3] THE EFFECT OF HEMODIALYSIS ON THE PHARMACOKINETICS OF TENOXICAM IN PATIENTS WITH END-STAGE RENAL-DISEASE
ALGHAMDI, MS
ALMOHANNA, FA
ALMUSTAFA, ZH
ALSAEED, IS
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 43 (02) : 197 - 199
[4] THE PHARMACOKINETICS OF AMINOGUANIDINE IN END-STAGE RENAL-DISEASE PATIENTS ON HEMODIALYSIS
FOOTE, EF
LOOK, ZM
GILES, P
KEANE, WF
HALSTENSON, CE
AMERICAN JOURNAL OF KIDNEY DISEASES, 1995, 25 (03) : 420 - 425
[5] Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease
Juliette Thariat
Marie-Christine Etienne-Grimaldi
Vincent Launay-Vacher
Arturo Soto-Matos
Carlos Fernandez-Teruel
Thomas Ghafari
Pierre-Yves Marcy
Gérard Milano
Nicole Renée
Lauris Gastaud
Antoine Thyss
Cancer Chemotherapy and Pharmacology, 2011, 68 : 1363 - 1367
[6] Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease
Thariat, Juliette
Etienne-Grimaldi, Marie-Christine
Launay-Vacher, Vincent
Soto-Matos, Arturo
Fernandez-Teruel, Carlos
Ghafari, Thomas
Marcy, Pierre-Yves
Milano, Gerard
Renee, Nicole
Gastaud, Lauris
Thyss, Antoine
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1363 - 1367
[7] Safety of Nirmatrelvir/Ritonavir in Dialysis Patients with COVID-19 The End of the Beginning?
Yilmam, Osman A. A.
Leaf, David E. E.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (04): : 427 - 429
[8] Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment
Manitpisitkul, Prasarn
Curtin, Christopher R.
Shalayda, Kevin
Wang, Shean-Sheng
Ford, Lisa
Heald, Donald L.
EPILEPSY RESEARCH, 2014, 108 (05) : 891 - 901
[9] Psychosocial Impact of COVID-19 Pandemic on Patients with End-Stage Kidney Disease on Hemodialysis
Lee, Jacqueline
Steel, Jennifer
Roumelioti, Maria-Eleni
Erickson, Sarah
Myaskovsky, Larissa
Yabes, Jonathan G.
Rollman, Bruce L.
Weisbord, Steven
Unruh, Mark
Jhamb, Manisha
KIDNEY360, 2020, 1 (12): : 1390 - 1397
[10] Safety, efficacy, and pharmacokinetics of nirmatrelvir and ritonavir in patients with severe COVID-19 and renal impairment: A case report
Zheng, Ren
Fan, Xudong
Zhou, Feng
Ye, Xiqian
Sun, Jing
Cheng, Junjie
Yuan, Yuan
Wang, Yu
Cai, Xinjun
Wei, Anqi
HELIYON, 2024, 10 (06)

← 1 2 3 4 5 →